Movatterモバイル変換


[0]ホーム

URL:


SG11202103316TA - Methods and compositions for modulation of tau proteins - Google Patents

Methods and compositions for modulation of tau proteins

Info

Publication number
SG11202103316TA
SG11202103316TASG11202103316TASG11202103316TASG11202103316TASG 11202103316T ASG11202103316T ASG 11202103316TASG 11202103316T ASG11202103316T ASG 11202103316TASG 11202103316T ASG11202103316T ASG 11202103316TASG 11202103316T ASG11202103316T ASG 11202103316TA
Authority
SG
Singapore
Prior art keywords
modulation
compositions
methods
tau proteins
tau
Prior art date
Application number
SG11202103316TA
Inventor
Brigit E Riley
Bryan Zeitler
Original Assignee
Sangamo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Therapeutics IncfiledCriticalSangamo Therapeutics Inc
Publication of SG11202103316TApublicationCriticalpatent/SG11202103316TA/en

Links

Classifications

Landscapes

SG11202103316TA2018-10-022019-10-02Methods and compositions for modulation of tau proteinsSG11202103316TA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201862740162P2018-10-022018-10-02
PCT/US2019/054339WO2020072677A1 (en)2018-10-022019-10-02Methods and compositions for modulation of tau proteins

Publications (1)

Publication NumberPublication Date
SG11202103316TAtrue SG11202103316TA (en)2021-04-29

Family

ID=69946993

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11202103316TASG11202103316TA (en)2018-10-022019-10-02Methods and compositions for modulation of tau proteins

Country Status (10)

CountryLink
US (2)US12318427B2 (en)
EP (1)EP3860618A4 (en)
JP (1)JP2022512579A (en)
KR (1)KR20210070344A (en)
CN (1)CN113226333A (en)
AU (1)AU2019355433A1 (en)
CA (1)CA3115156A1 (en)
IL (1)IL281972A (en)
SG (1)SG11202103316TA (en)
WO (1)WO2020072677A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
KR102674612B1 (en)2016-12-012024-06-14상가모 테라퓨틱스, 인코포레이티드 Tau modulators and methods and compositions for their delivery
SG11202103316TA (en)2018-10-022021-04-29Sangamo Therapeutics IncMethods and compositions for modulation of tau proteins
CA3163576A1 (en)2019-12-042021-06-10Sangamo Therapeutics, Inc.Novel compositions and methods for producing recombinant aav
KR20220131273A (en)2020-01-222022-09-27상가모 테라퓨틱스, 인코포레이티드 Zinc Finger Protein Transcription Factor to Inhibit Tau Expression
JP7749244B2 (en)*2020-07-092025-10-06株式会社モダリス Treatment method for Alzheimer's disease targeting the MAPT gene
KR102775835B1 (en)*2021-10-252025-03-06한국과학기술연구원A preparation method for animal model of alzheimer's disease and animal model of alzheimer's disease using the same

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4217344A (en)1976-06-231980-08-12L'orealCompositions containing aqueous dispersions of lipid spheres
US4235871A (en)1978-02-241980-11-25Papahadjopoulos Demetrios PMethod of encapsulating biologically active materials in lipid vesicles
US4186183A (en)1978-03-291980-01-29The United States Of America As Represented By The Secretary Of The ArmyLiposome carriers in chemotherapy of leishmaniasis
US4261975A (en)1979-09-191981-04-14Merck & Co., Inc.Viral liposome particle
US4485054A (en)1982-10-041984-11-27Lipoderm Pharmaceuticals LimitedMethod of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en)1983-01-061985-02-26Technology Unlimited, Inc.Masking of liposomes from RES recognition
US4946787A (en)1985-01-071990-08-07Syntex (U.S.A.) Inc.N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en)1985-01-071990-01-30Syntex (U.S.A.) Inc.N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en)1985-01-071991-09-17Syntex (U.S.A.) Inc.N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en)1985-03-151989-01-10The United States Of America As Represented By The Department Of Health And Human ServicesAdeno-associated virus as eukaryotic expression vector
US4774085A (en)1985-07-091988-09-27501 Board of Regents, Univ. of TexasPharmaceutical administration systems containing a mixture of immunomodulators
US5422251A (en)1986-11-261995-06-06Princeton UniversityTriple-stranded nucleic acids
US4837028A (en)1986-12-241989-06-06Liposome Technology, Inc.Liposomes with enhanced circulation time
US5176996A (en)1988-12-201993-01-05Baylor College Of MedicineMethod for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5264618A (en)1990-04-191993-11-23Vical, Inc.Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en)1990-05-031991-11-14Vical, Inc.Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en)1990-10-301992-12-22Applied Immune Sciences, Inc.Production of recombinant adeno-associated virus vectors
US5420032A (en)1991-12-231995-05-30Universitge LavalHoming endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en)1992-05-051998-08-11Institut PasteurNucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5587308A (en)1992-06-021996-12-24The United States Of America As Represented By The Department Of Health & Human ServicesModified adeno-associated virus vector capable of expression from a novel promoter
WO1994026877A1 (en)1993-05-171994-11-24The Regents Of The University Of CaliforniaRibozyme gene therapy for hiv infection and aids
US6140466A (en)1994-01-182000-10-31The Scripps Research InstituteZinc finger protein derivatives and methods therefor
EP0770129B1 (en)1994-01-182005-11-23The Scripps Research InstituteZinc finger protein derivatives and methods therefor
CA2186118C (en)1994-03-232010-10-19Richard W. HansonCompacted nucleic acids and their delivery to cells
US5585245A (en)1994-04-221996-12-17California Institute Of TechnologyUbiquitin-based split protein sensor
GB9824544D0 (en)1998-11-091999-01-06Medical Res CouncilScreening system
EP2022856B1 (en)1994-08-202011-09-14Gendaq LimitedImprovements in or relating to binding proteins for recognition of DNA
US5789538A (en)1995-02-031998-08-04Massachusetts Institute Of TechnologyZinc finger proteins with high affinity new DNA binding specificities
US5928638A (en)1996-06-171999-07-27Systemix, Inc.Methods for gene transfer
US5925523A (en)1996-08-231999-07-20President & Fellows Of Harvard CollegeIntraction trap assay, reagents and uses thereof
US6342345B1 (en)1997-04-022002-01-29The Board Of Trustees Of The Leland Stanford Junior UniversityDetection of molecular interactions by reporter subunit complementation
GB9710809D0 (en)1997-05-231997-07-23Medical Res CouncilNucleic acid binding proteins
GB9710807D0 (en)1997-05-231997-07-23Medical Res CouncilNucleic acid binding proteins
DE69942334D1 (en)1998-03-022010-06-17Massachusetts Inst Technology POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS
ES2257051T3 (en)1998-05-272006-07-16Avigen, Inc. ADMINISTRATION POTENTIATED BY CONVECTION OF AAV VECTORS CODING AADC.
US6140081A (en)1998-10-162000-10-31The Scripps Research InstituteZinc finger binding domains for GNN
US6534261B1 (en)1999-01-122003-03-18Sangamo Biosciences, Inc.Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en)1999-09-142003-07-29Sangamo Bioscience, Inc.Functional genomics using zinc finger proteins
US7013219B2 (en)1999-01-122006-03-14Sangamo Biosciences, Inc.Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en)1999-01-122002-09-17Sangamo Biosciences, Inc.Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
IL150069A0 (en)1999-12-062002-12-01Sangamo Biosciences IncMethods of using randomized libraries of zinc finger proteins for the identification of gene function
CA2398155C (en)2000-01-242011-07-19Sangamo Biosciences, Inc.Methods and compositions for linking binding domains in nucleic acid binding proteins
DE60143192D1 (en)2000-02-082010-11-18Sangamo Biosciences Inc CELLS FOR THE DISCOVERY OF MEDICAMENTS
US20020061512A1 (en)2000-02-182002-05-23Kim Jin-SooZinc finger domains and methods of identifying same
US20030044787A1 (en)2000-05-162003-03-06Joung J. KeithMethods and compositions for interaction trap assays
JP2002060786A (en)2000-08-232002-02-26Kao Corp Bactericidal antifouling agent for hard surfaces
JP2004537260A (en)2000-12-072004-12-16サンガモ バイオサイエンシーズ, インコーポレイテッド Regulation of angiogenesis by zinc finger proteins
GB0108491D0 (en)2001-04-042001-05-23Gendaq LtdEngineering zinc fingers
US7182944B2 (en)2001-04-252007-02-27The United States Of America As Represented By The Department Of Health And Human ServicesMethods of increasing distribution of nucleic acids
JP2005500061A (en)2001-08-202005-01-06ザ スクリップス リサーチ インスティテュート Zinc finger binding domain for CNN
KR20040065235A (en)2001-12-072004-07-21주식회사 툴젠Phenotypic screen of chimeric proteins
JP4769417B2 (en)2001-12-172011-09-07ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Adeno-associated virus (AAV) serotype 9 sequences, vectors containing the same and uses thereof
US7074596B2 (en)2002-03-252006-07-11Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical CollegeSynthesis and use of anti-reverse mRNA cap analogues
JP4716517B2 (en)2003-06-092011-07-06アルナイラム ファーマシューティカルズ, インコーポレイテッド Methods for treating neurodegenerative diseases
US7888121B2 (en)2003-08-082011-02-15Sangamo Biosciences, Inc.Methods and compositions for targeted cleavage and recombination
US8409861B2 (en)2003-08-082013-04-02Sangamo Biosciences, Inc.Targeted deletion of cellular DNA sequences
WO2005030959A1 (en)2003-09-252005-04-07Chiba-PrefectureMicroarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis
US20060239966A1 (en)2003-10-202006-10-26Tornoee JensIn vivo gene therapy of parkinson's disease
BRPI0516463B1 (en)2004-10-052021-05-11Genzyme Corporation delivery system for one or more materials
EP1877583A2 (en)2005-05-052008-01-16Arizona Board of Regents on behalf of the Unversity of ArizonaSequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences
JP5238503B2 (en)2005-08-232013-07-17ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Anti-reflux cannula and system for chronic delivery of therapeutic agents using enhanced convection delivery
ES2384440T3 (en)2005-10-182012-07-04Precision Biosciences Rationally designed meganucleases with sequence specificity and altered DNA binding affinity
WO2007127803A2 (en)2006-04-252007-11-08The Regents Of The University Of CaliforniaAdministration of growth factors for the treatment of cns disorders
DE602007005634D1 (en)2006-05-252010-05-12Sangamo Biosciences Inc VARIANT FOKI CREVICE HOLLAND DOMAINS
DK2049663T3 (en)2006-08-112015-06-01Dow Agrosciences Llc ZINC FINGER NUCLEASE-MEDIATED HOMOLOGOUS RECOMBINATION
US7837668B2 (en)2006-10-102010-11-23Ceregene, Inc.Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of same
PT2167523E (en)2007-06-192014-09-22Univ Louisiana StateSynthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
CA2700231C (en)2007-09-272018-09-18Sangamo Biosciences, Inc.Rapid in vivo identification of biologically active nucleases
JP2011521643A (en)2008-05-282011-07-28サンガモ バイオサイエンシーズ, インコーポレイテッド Composition for linking a DNA binding domain and a cleavage domain
CA2893175C (en)2008-06-102016-09-06Sangamo Biosciences, Inc.Methods and compositions for generation of bax- and bak-deficient cell lines
AU2009283194B2 (en)2008-08-222014-10-16Sangamo Therapeutics, Inc.Methods and compositions for targeted single-stranded cleavage and targeted integration
US20110016539A1 (en)2008-12-042011-01-20Sigma-Aldrich Co.Genome editing of neurotransmission-related genes in animals
US20110023153A1 (en)2008-12-042011-01-27Sigma-Aldrich Co.Genomic editing of genes involved in alzheimer's disease
KR20100080068A (en)2008-12-312010-07-08주식회사 툴젠A novel zinc finger nuclease and uses thereof
EP2206723A1 (en)2009-01-122010-07-14Bonas, UllaModular DNA-binding domains
UA107571C2 (en)2009-04-032015-01-26 PHARMACEUTICAL COMPOSITION
CA2769262C (en)2009-07-282019-04-30Sangamo Biosciences, Inc.Methods and compositions for treating trinucleotide repeat disorders
KR20120097484A (en)2009-07-312012-09-04에트리스 게엠베하Rna with a combination of unmodified and modified nucleotides for protein expression
US8956828B2 (en)2009-11-102015-02-17Sangamo Biosciences, Inc.Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US20110135613A1 (en)2009-12-032011-06-09The J. David Gladstone InstitutesMethods for treating apolipoprotein e4-associated disorders
EP2615106B1 (en)2010-02-082018-04-25Sangamo Therapeutics, Inc.Engineered cleavage half-domains
HRP20200254T1 (en)2010-05-032020-05-29Sangamo Therapeutics, Inc. PREPARATIONS FOR CONNECTING ZINC FINGER MODULE
EP2571512B1 (en)2010-05-172017-08-23Sangamo BioSciences, Inc.Novel dna-binding proteins and uses thereof
US9322023B2 (en)2011-10-062016-04-26Cornell UniversityConstructs and methods for the assembly of biological pathways
US9458205B2 (en)2011-11-162016-10-04Sangamo Biosciences, Inc.Modified DNA-binding proteins and uses thereof
CN108285491B (en)2012-02-292021-08-10桑格摩生物科学股份有限公司Methods and compositions for treating huntington's disease
BR112014020753B1 (en)2012-03-022021-10-05Nissan Motor Co., Ltd THREE-DIMENSIONAL OBJECT DETECTION DEVICE
EP2931899A1 (en)2012-12-122015-10-21The Broad Institute, Inc.Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
MX2015012621A (en)2013-03-142016-05-31Ionis Pharmaceuticals IncCompositions and methods for modulating tau expression.
CA2910489A1 (en)2013-05-152014-11-20Sangamo Biosciences, Inc.Methods and compositions for treatment of a genetic condition
AU2014274840B2 (en)2013-06-052020-03-12Duke UniversityRNA-guided gene editing and gene regulation
TWI702046B (en)2013-07-192020-08-21美商Ionis製藥公司Compositions for modulating tau expression
US9359599B2 (en)2013-08-222016-06-07President And Fellows Of Harvard CollegeEngineered transcription activator-like effector (TALE) domains and uses thereof
WO2015031619A1 (en)2013-08-282015-03-05Sangamo Biosciences, Inc.Compositions for linking dna-binding domains and cleavage domains
ES2739288T3 (en)2013-09-132020-01-30California Inst Of Techn Selective recovery
CN106030310B (en)2013-12-132019-01-04通用医疗公司Soluble high-molecular amount (HMW) TAU type and its application
JP6594891B2 (en)2014-03-182019-10-23サンガモ セラピューティクス, インコーポレイテッド Methods and compositions for modulating zinc finger protein expression
WO2015153760A2 (en)2014-04-012015-10-08Sangamo Biosciences, Inc.Methods and compositions for prevention or treatment of a nervous system disorder
BR112016025849A2 (en)*2014-05-082017-10-17Chdi Foundation Inc methods and compositions for the treatment of huntington's disease
WO2015188056A1 (en)2014-06-052015-12-10Sangamo Biosciences, Inc.Methods and compositions for nuclease design
RU2017127609A (en)2015-02-042019-03-04Ф. Хоффманн-Ля Рош Аг ANTISENSE OLIGOMERS TAU-PROTEIN AND THEIR APPLICATION
US20170035860A1 (en)2015-04-022017-02-09Alexander C. FlynnCompositions and methods for treatment of neurogenerative diseases
WO2017011556A1 (en)*2015-07-132017-01-19The General Hospital CorporationRare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof
PE20181206A1 (en)2015-10-282018-07-23Sangamo Therapeutics Inc SPECIFIC LIVER CONSTRUCTIONS, FACTOR VIII EXPRESSION CASSETTES AND METHODS OF USE OF THESE
US10724020B2 (en)2016-02-022020-07-28Sangamo Therapeutics, Inc.Compositions for linking DNA-binding domains and cleavage domains
WO2017197141A2 (en)2016-05-132017-11-16Sangamo Therapeutics, Inc.Targeted treatment of androgenic alopecia
KR20240144493A (en)2016-08-242024-10-02상가모 테라퓨틱스, 인코포레이티드Engineered target specific nucleases
CN110325635B (en)2016-08-242023-12-26桑格摩生物治疗股份有限公司Regulation of gene expression using engineered nucleases
WO2018039471A2 (en)2016-08-252018-03-01Trustees Of Boston UniversitySynthetic transcriptional and epigenetic regulators based on engineered, orthogonal zinc finger proteins
US10960085B2 (en)2016-09-072021-03-30Sangamo Therapeutics, Inc.Modulation of liver genes
US11371023B2 (en)2016-11-222022-06-28Wisconsin Alumni Research FoundationArtificial transcription factors and uses thereof
KR102674612B1 (en)2016-12-012024-06-14상가모 테라퓨틱스, 인코포레이티드 Tau modulators and methods and compositions for their delivery
WO2020072684A1 (en)2018-10-022020-04-09Sangamo Therapeutics, Inc.Engineered genetic modulators
SG11202103316TA (en)2018-10-022021-04-29Sangamo Therapeutics IncMethods and compositions for modulation of tau proteins
KR20220131273A (en)2020-01-222022-09-27상가모 테라퓨틱스, 인코포레이티드 Zinc Finger Protein Transcription Factor to Inhibit Tau Expression

Also Published As

Publication numberPublication date
WO2020072677A1 (en)2020-04-09
EP3860618A4 (en)2022-06-08
IL281972A (en)2021-05-31
EP3860618A1 (en)2021-08-11
CN113226333A (en)2021-08-06
KR20210070344A (en)2021-06-14
AU2019355433A1 (en)2021-05-06
US12318427B2 (en)2025-06-03
US20200101133A1 (en)2020-04-02
JP2022512579A (en)2022-02-07
US20250268981A1 (en)2025-08-28
CA3115156A1 (en)2020-04-09

Similar Documents

PublicationPublication DateTitle
SG11202103316TA (en)Methods and compositions for modulation of tau proteins
EP3856787A4 (en)SIRPalpha BINDING PROTEINS AND METHODS OF USE THEREOF
EP3688012A4 (en)Compounds and methods of modulating protein degradation
EP3661966A4 (en) ANTI-CD39 ANTIBODIES, COMPOSITIONS OF ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
EP3589291A4 (en) COMPOSITIONS AND METHODS OF INHIBITION OF CELL LINE SPECIFIC PROTEINS
ZA201902297B (en)Low-viscosity antigen binding proteins and methods of making them
EP3576782A4 (en) CONSTRUCTIVE PEPTIDE COMPOSITIONS AND METHOD OF USING THEREOF
IL273980A (en)Compositions of phosphorylated tau peptides and uses thereof
EP3601359A4 (en) PROCEDURES AND COMPOSITIONS FOR MODULATION OF IMMUNE CELLS
IL284157A (en)Anti-pd-1 binding proteins and methods of use thereof
ZA201902968B (en)Method for increasing the secretion levels of interleukin 2 and proteins derived from it
IL279201A (en)Multi-specific binding proteins and methods of use thereof
IL290595A (en)Compositions and methods for modulating splicing and protein expression
IL284156A (en)Anti-ctla-4 binding proteins and methods of use thereof
IL280280A (en)Compositions of fcrn antibodies and methods of use thereof
EP3807319A4 (en) COMPOSITIONS AND METHODS FOR INDUCING PHAGOCYTOSIS
EP3218370A4 (en)Methods and compositions for inhibition of bromodomain and extraterminal proteins
EP3806840A4 (en) COMPOSITIONS AND METHODS OF MODULATION OF ELOVL2
IL276059A (en)Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
IL284364A (en)Anti-pd-l1 binding proteins and methods of use thereof
HK40059467A (en)Methods and compositions for modulation of tau proteins
EP3452074A4 (en) COMPOSITIONS AND METHODS FOR MODULATION OF ABETA PROTEIN
HK40062126A (en)Anti-pd-1 binding proteins and methods of use thereof
HK40037283B (en)Nectin-4 binding proteins and methods of use thereof
HK40060243A (en)Compositions and methods of enhancing immunotherapies

[8]ページ先頭

©2009-2025 Movatter.jp